Compliance with the airworthiness directive, if any, may be obtained from the Engine Certification Office.

(c) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the aircraft to a location where the requirements of this AD can be accomplished.

(d) The actions required by this AD shall be done in accordance with the following R-R SB:

<table>
<thead>
<tr>
<th>Document No.</th>
<th>Pages</th>
<th>Revision</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>RB 211–73–B048.</td>
<td>1–6</td>
<td>1</td>
<td>July 22, 1994</td>
</tr>
<tr>
<td></td>
<td>7,8</td>
<td>Original</td>
<td>June 3, 1994</td>
</tr>
<tr>
<td></td>
<td>9–12</td>
<td>1</td>
<td>July 22, 1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>July 22, 1994</td>
</tr>
</tbody>
</table>

This incorporation by reference was approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from Rolls-Royce, plc, P.O. Box 31, Moor Lane, Derby, DE248BJ, United Kingdom; telephone 1332–249428, fax 1332–249423.

Copies may be inspected at the FAA, New England Region, Office of the Assistant Chief Counsel, 21 New England Executive Park, Burlington, MA; or at the Office of the Federal Register, 800 North Capitol Street NW, suite 700, Washington, DC.

(e) This amendment becomes effective on September 10, 1996.

Issued in Burlington, Massachusetts, on June 11, 1996.

James C. Jones,
Acting Manager, Engine and Propeller Directorate, Aircraft Certification Service.

[FR Doc. 96–17535 Filed 7–11–96; 8:45 am]
BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

Advisory Committees; Conversion of Ad Hoc Advisory Committee to Standing Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the standing advisory committees’ regulations to add the name and function of the Transmissible Spongiform Encephalopathies Advisory Committee (formerly Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease). Appearing elsewhere in this issue of the Federal Register is a notice announcing the renewal of this advisory committee. A notice requesting nominations for membership on this committee will publish at a later date. This action is being taken to incorporate this committee into the agency’s list of standing advisory committees because it will no longer be serving in an ad hoc capacity.

EFFECTIVE DATE: July 12, 1996.

FOR FURTHER INFORMATION CONTACT: Donna M. Combs, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

SUPPLEMENTARY INFORMATION: FDA is announcing that the name of the Ad Hoc Advisory Committee on Creutzfeldt-Jakob Disease has been changed. The committee was established on June 21, 1995, to advise the Commissioner of Food and Drugs regarding the safety of blood products obtained or prepared from one or more donations from a donor who, after donation, was diagnosed with Creutzfeldt-Jakob Disease. The committee was chartered for the duration of 1 year.

The Commissioner has now formally determined that there is a continuing need for this committee, that the name and function of the committee will be changed to more accurately describe the committee, and that the committee will no longer be serving in an ad hoc capacity. The name “Transmissible Spongiform Encephalopathies Advisory Committee” will more accurately describe the subject area for which the committee is responsible. The change is consistent with the expanded function of the committee.

The committee’s new function is to review and evaluate available scientific data concerning the safety of products which may be at risk for transmission of spongiform encephalopathies having an impact on the public health as determined by the Commissioner of Food and Drugs. The committee will also make recommendations to the Commissioner regarding the regulation of such products.

Management and support services for the committee will continue to be provided by FDA’s Center for Biologics Evaluation and Research. In this document, FDA is formally incorporating this committee into the agency’s list of standing advisory committees by adding a new paragraph in 21 CFR 14.100(b).

Publication of this final rule constitutes a final action on this change under the Administrative Procedure Act. Under 5 U.S.C. 553(b)(3)(B) and (d) and 21 CFR 10.40(d) and (e), the agency finds good cause to dispense with notice and public procedure and to proceed to an immediately effective regulation. Such notice and procedures are unnecessary and are not in the public interest, because the final rule is merely codifying the new name and expanded function of the advisory committee, as well as its status as a standing advisory committee, and when effective will reflect the current committee charter.

List of Subjects in 21 CFR Part 14

Administrative practice and procedure, Advisory committees, Color additives, Drugs, Radiation protection.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 14 is amended as follows:

PART 14—PUBLIC HEARING BEFORE A PUBLIC ADVISORY COMMITTEE

1. The authority citation for 21 CFR part 14 continues to read as follows:


2. Section 14.100 is amended by adding new paragraph (b)(6) to read as follows:

§ 14.100 List of standing advisory committees.

(b) * * * * * *(6) Transmissible Spongiform Encephalopathies Advisory Committee.

(i) Date established: June 21, 1995.

(ii) Function: Reviews and evaluates available scientific data concerning the safety of products which may be at risk for transmission of spongiform encephalopathies having an impact on the public health.

Dated: July 5, 1996.
Michael A. Friedman,
Deputy Commissioner for Operations.

[FR Doc. 96–17686 Filed 7–11–96; 8:45 am]
BILLING CODE 4160–01–F